Tango Therapeutics, Inc. (TNGX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
26/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 8 wins, 4 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinTNGX / S&P 49.43% / 15.20% |
WinTNGX / S&P 121.47% / 15.00% |
LoseTNGX / S&P -34.85% / 50.40% |
| 2026-Q12/3 |
WinTNGX / S&P 136.12% / -4.33% |
WinTNGX / S&P 39.04% / 11.30% |
LoseTNGX / S&P -30.58% / 27.70% |
| 2025-Q42/3 |
WinTNGX / S&P 5.48% / 2.65% |
WinTNGX / S&P 48.29% / 9.00% |
LoseTNGX / S&P -26.67% / 13.40% |
| 2025-Q32/3 |
WinTNGX / S&P 64.06% / 8.12% |
WinTNGX / S&P 53.28% / 4.61% |
LoseTNGX / S&P -20.69% / 13.45% |
| 2025-Q22/3 |
WinTNGX / S&P 273.72% / 10.94% |
LoseTNGX / S&P -42.84% / 4.83% |
WinTNGX / S&P 17.86% / 10.63% |
| 2025-Q11/3 |
LoseTNGX / S&P -55.66% / -4.27% |
WinTNGX / S&P 10.10% / 4.98% |
LoseTNGX / S&P 9.01% / 10.57% |
| 2024-Q42/3 |
LoseTNGX / S&P -59.87% / 2.41% |
WinTNGX / S&P 15.18% / 5.25% |
WinTNGX / S&P 11.11% / 6.15% |
| 2024-Q31/3 |
LoseTNGX / S&P -10.26% / 5.89% |
WinTNGX / S&P 15.67% / 5.89% |
LoseTNGX / S&P 4.50% / 6.11% |
| 2024-Q22/3 |
WinTNGX / S&P 8.06% / 4.28% |
WinTNGX / S&P 26.16% / 5.38% |
LoseTNGX / S&P -7.44% / 5.12% |
| 2024-Q11/3 |
LoseTNGX / S&P -19.80% / 10.56% |
WinTNGX / S&P 49.72% / 5.71% |
LoseTNGX / S&P -11.90% / 5.59% |
| 2023-Q41/3 |
LoseTNGX / S&P -12.08% / 11.69% |
WinTNGX / S&P 46.93% / 6.81% |
LoseTNGX / S&P -12.20% / 7.78% |
| 2023-Q33/3 |
WinTNGX / S&P 239.16% / -3.27% |
WinTNGX / S&P 55.21% / 7.52% |
WinTNGX / S&P -4.31% / -5.03% |
| 2023-Q22/3 |
LoseTNGX / S&P -15.95% / 8.74% |
WinTNGX / S&P 40.21% / 9.50% |
WinTNGX / S&P 9.01% / -8.57% |
| 2023-Q11/3 |
LoseTNGX / S&P -45.52% / 7.50% |
LoseTNGX / S&P -31.71% / 10.77% |
WinTNGX / S&P 36.96% / -15.69% |
| 2022-Q41/3 |
WinTNGX / S&P 100.28% / 7.56% |
LoseTNGX / S&P -32.89% / 11.88% |
LoseTNGX / S&P TNGX unavailable / -17.99% |
| 2022-Q30/3 |
LoseTNGX / S&P -20.09% / -4.88% |
LoseTNGX / S&P -40.29% / 13.47% |
LoseTNGX / S&P TNGX unavailable / -1.41% |
| 2022-Q20/3 |
LoseTNGX / S&P -40.24% / -16.10% |
LoseTNGX / S&P 7.19% / 13.71% |
LoseTNGX / S&P TNGX unavailable / 11.04% |
| 2022-Q10/3 |
LoseTNGX / S&P -30.71% / -4.60% |
LoseTNGX / S&P TNGX unavailable / 15.97% |
LoseTNGX / S&P TNGX unavailable / 42.23% |
| 2021-Q40/3 |
LoseTNGX / S&P -15.39% / 11.03% |
LoseTNGX / S&P TNGX unavailable / 15.00% |
LoseTNGX / S&P TNGX unavailable / 96.40% |
| 2021-Q31/3 |
WinTNGX / S&P 13.62% / 0.58% |
LoseTNGX / S&P TNGX unavailable / 10.77% |
LoseTNGX / S&P TNGX unavailable / 69.42% |
| 2021-Q20/3 |
LoseTNGX / S&P 2.34% / 8.55% |
LoseTNGX / S&P TNGX unavailable / 6.58% |
LoseTNGX / S&P TNGX unavailable / 51.81% |
| 2021-Q10/3 |
LoseTNGX / S&P -2.80% / 6.17% |
LoseTNGX / S&P TNGX unavailable / -1.06% |
LoseTNGX / S&P TNGX unavailable / 7.39% |
| 2020-Q40/3 |
LoseTNGX / S&P 10.42% / 12.15% |
LoseTNGX / S&P TNGX unavailable / -3.72% |
LoseTNGX / S&P TNGX unavailable / -33.42% |
| 2020-Q30/3 |
LoseTNGX / S&P TNGX unavailable / 8.93% |
LoseTNGX / S&P TNGX unavailable / -2.04% |
LoseTNGX / S&P TNGX unavailable / -27.10% |
| 2020-Q20/3 |
LoseTNGX / S&P TNGX unavailable / 20.54% |
LoseTNGX / S&P TNGX unavailable / -0.46% |
LoseTNGX / S&P TNGX unavailable / -27.11% |
| 2020-Q10/3 |
LoseTNGX / S&P TNGX unavailable / -19.60% |
LoseTNGX / S&P TNGX unavailable / 3.47% |
LoseTNGX / S&P TNGX unavailable / -14.75% |
| 2019-Q40/3 |
LoseTNGX / S&P TNGX unavailable / 9.07% |
LoseTNGX / S&P TNGX unavailable / 5.36% |
LoseTNGX / S&P TNGX unavailable / 2.99% |
| 2019-Q30/3 |
LoseTNGX / S&P TNGX unavailable / 1.70% |
LoseTNGX / S&P TNGX unavailable / 5.02% |
LoseTNGX / S&P TNGX unavailable / 0.21% |
| 2019-Q20/3 |
LoseTNGX / S&P TNGX unavailable / 4.30% |
LoseTNGX / S&P TNGX unavailable / 6.64% |
LoseTNGX / S&P TNGX unavailable / 8.65% |
| 2019-Q10/3 |
LoseTNGX / S&P TNGX unavailable / 13.65% |
LoseTNGX / S&P TNGX unavailable / 8.12% |
LoseTNGX / S&P TNGX unavailable / 14.29% |
| 2018-Q40/3 |
LoseTNGX / S&P TNGX unavailable / -13.52% |
LoseTNGX / S&P TNGX unavailable / 9.05% |
LoseTNGX / S&P TNGX unavailable / 18.23% |
| 2018-Q30/3 |
LoseTNGX / S&P TNGX unavailable / 7.71% |
LoseTNGX / S&P TNGX unavailable / 10.21% |
LoseTNGX / S&P TNGX unavailable / 19.06% |
| 2018-Q20/3 |
LoseTNGX / S&P TNGX unavailable / 3.43% |
LoseTNGX / S&P TNGX unavailable / 9.03% |
LoseTNGX / S&P TNGX unavailable / 14.46% |
| 2018-Q10/3 |
LoseTNGX / S&P TNGX unavailable / -0.76% |
LoseTNGX / S&P TNGX unavailable / 7.68% |
LoseTNGX / S&P TNGX unavailable / 12.46% |
| 2017-Q40/3 |
LoseTNGX / S&P TNGX unavailable / 6.64% |
LoseTNGX / S&P TNGX unavailable / 7.03% |
LoseTNGX / S&P TNGX unavailable / 13.82% |
| 2017-Q30/3 |
LoseTNGX / S&P TNGX unavailable / 4.48% |
LoseTNGX / S&P TNGX unavailable / 5.68% |
LoseTNGX / S&P TNGX unavailable / 17.57% |
| 2017-Q20/3 |
LoseTNGX / S&P TNGX unavailable / 3.09% |
LoseTNGX / S&P TNGX unavailable / 4.83% |
LoseTNGX / S&P TNGX unavailable / 17.74% |
| 2017-Q10/3 |
LoseTNGX / S&P TNGX unavailable / 6.07% |
LoseTNGX / S&P TNGX unavailable / 3.67% |
LoseTNGX / S&P TNGX unavailable / 13.32% |
| 2016-Q40/3 |
LoseTNGX / S&P TNGX unavailable / 3.82% |
LoseTNGX / S&P TNGX unavailable / 2.09% |
LoseTNGX / S&P TNGX unavailable / 7.05% |
| 2016-Q30/3 |
LoseTNGX / S&P TNGX unavailable / 3.85% |
LoseTNGX / S&P TNGX unavailable / 0.20% |
LoseTNGX / S&P TNGX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | TNGX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 276.75% | 20.78% |
| Annualized return | 276.75% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | TNGX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 110.49% | 83.14% |
| Annualized return | 16.05% | 12.86% |
10Y · 2020-09-03 to 2026-08-27
| Metric | TNGX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 147.12% | 319.30% |
| Annualized return | 9.47% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |